Oppenheimer Assigned a Hold Rating to Insulet Corp.

By Ryan Adsit

In a report released today, Steven Lichtman from Oppenheimer assigned a Hold rating to Insulet Corp. (NASDAQ: PODD), with a price target of $39. The company’s shares opened today at $35.50.

According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -2.2% and a 55.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Integra Lifesciences.

Insulet Corp. has an analyst consensus of Moderate Buy, with a price target consensus of $45.40.

The company has a one year high of $45.60 and a one year low of $23.94. Currently, Insulet Corp. has an average volume of 547.8K.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PODD in relation to earlier this year. Last month, Patrick Sullivan, the President & CEO of PODD bought 3,075 shares for a total of $99,968.

Insulet Corp. is an innovative medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It’s current product offering consists of diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Billerica, MA.